Bausch Health Companies (BHC) Other Non-Current Liabilities (2009 - 2026)
Bausch Health Companies (BHC) reported Other Non-Current Liabilities of $763.0 million for Q1 2026, little changed on a YoY basis from $761.0 million in Q1 2025, and down 3.78% sequentially from $793.0 million in Q4 2025.
Bausch Health Companies (BHC) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Other Non-Current Liabilities data on file, last reported at $763.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities changed 0.26% year-over-year to $763.0 million; the trailing twelve-month figure through Mar 2026 stood at $763.0 million (changed 0.26% YoY), and the FY2025 full-year result was $793.0 million, up 11.22% from the prior year.
- Other Non-Current Liabilities fell to $763.0 million in Q1 2026, from $793.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $877.0 million in Q2 2025 to a low of $524.0 million in Q2 2022.
- A 5-year average of $733.4 million and a median of $746.0 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities slumped 46.26% in 2022 and jumped 42.18% in 2023, its largest moves.
- Tracing BHC's Other Non-Current Liabilities over 5 years: stood at $741.0 million in 2022, then advanced by 4.72% to $776.0 million in 2023, then decreased by 8.12% to $713.0 million in 2024, then grew by 11.22% to $793.0 million in 2025, then decreased by 3.78% to $763.0 million in 2026.
- Business Quant data shows BHC's Other Non-Current Liabilities at $763.0 million in Q1 2026, $793.0 million in Q4 2025, and $843.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 763.00 Mn |
| Dec 31, 2025 | 793.00 Mn |
| Sep 30, 2025 | 843.00 Mn |
| Jun 30, 2025 | 877.00 Mn |
| Mar 31, 2025 | 761.00 Mn |
| Dec 31, 2024 | 713.00 Mn |
| Sep 30, 2024 | 805.00 Mn |
| Jun 30, 2024 | 745.00 Mn |
| Mar 31, 2024 | 751.00 Mn |
| Dec 31, 2023 | 776.00 Mn |
| Sep 30, 2023 | 721.00 Mn |
| Jun 30, 2023 | 745.00 Mn |
| Mar 31, 2023 | 746.00 Mn |
| Dec 31, 2022 | 741.00 Mn |
| Sep 30, 2022 | 619.00 Mn |
| Jun 30, 2022 | 524.00 Mn |
| Mar 31, 2022 | 544.00 Mn |
| Dec 31, 2021 | 653.00 Mn |
| Sep 30, 2021 | 872.00 Mn |
| Jun 30, 2021 | 975.00 Mn |